Compare Tencent Music Entertainment Group - ADR (TME) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Tango Therapeutics Inc. — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.35 (market cap $13.81B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 3.7× Tango Therapeutics Inc.'s market cap, and Tencent Music Entertainment Group - ADR pays a 2.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tencent Music Entertainment Group - ADR for 68 Days and Tango Therapeutics Inc. for 0 Days on average.
| TME | TNGX | |
|---|---|---|
Market Cap | $13.81B | $3.75B |
Volume | 6,097,902 | 9,619,106 |
Sector | Media | Health |
52-Week High | $23.71 | $32.90 |
52-Week Low | $7.74 | $7.50 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $11.76B | $2.77B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tencent Music Entertainment (TME) trades at $8.48, up 0.36% on the day, with a bullish technical signal and strong fundamentals. Revenue grew to $32.9B in 2025, with net income surging to $11.06B, and valuation ratios like a P/E of 9.94 appear attractive. Recent news highlights a $1B notes offering and a $400M share repurchase program, signaling financial discipline.
The outlook is positive with a consensus price target of $12.50, offering 47% upside, but risks include intense competition and regulatory oversight. Earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing, indicating potential volatility in performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
